Citigroup Has Lowered Expectations for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX) had its target price cut by Citigroup from $130.00 to $125.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price objective would suggest a potential upside of 35.80% from the stock’s previous close.

Several other equities research analysts have also weighed in on BNTX. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. Canaccord Genuity Group set a $142.00 target price on shares of BioNTech in a report on Wednesday. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Morgan Stanley dropped their price objective on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. Finally, HC Wainwright restated a “buy” rating and set a $130.00 target price on shares of BioNTech in a research report on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $127.81.

BioNTech Stock Performance

NASDAQ BNTX traded up $0.70 on Wednesday, hitting $92.05. 883,123 shares of the stock traded hands, compared to its average volume of 1,024,362. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80. The business’s fifty day moving average is $91.47 and its two-hundred day moving average is $97.17. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00. The firm has a market capitalization of $23.28 billion, a price-to-earnings ratio of -15.68 and a beta of 1.27.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, May 4th. The company reported ($2.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.52) by $0.26. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%.The firm had revenue of $136.71 million for the quarter, compared to analyst estimates of $207.42 million. During the same period in the previous year, the company posted ($1.73) earnings per share. The business’s revenue was down 35.4% on a year-over-year basis. As a group, equities analysts anticipate that BioNTech will post -5.79 EPS for the current fiscal year.

BioNTech announced that its board has authorized a stock buyback plan on Thursday, May 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 4.2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BNTX. Larson Financial Group LLC lifted its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. EFG International AG bought a new position in shares of BioNTech during the 4th quarter valued at about $29,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares in the last quarter. Finally, Vestcor Inc purchased a new position in shares of BioNTech during the fourth quarter worth approximately $153,000. Institutional investors own 15.52% of the company’s stock.

Key Stories Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Morgan Stanley initiated or reiterated a Buy rating on BioNTech, suggesting the firm sees potential upside from the company’s oncology pipeline and long-term growth strategy. BioNTech Receives a Buy from Morgan Stanley
• Positive Sentiment: BioNTech reported a strong financial position, with €16.6 billion in cash, cash equivalents and investments. Its development pipeline includes 14 ongoing pivotal trials, six pivotal-trial initiations in 2026 and three expected late-stage readouts later this year. BioNTech Second Quarter 2026 Results and Corporate Update
• Positive Sentiment: BioNTech named Guido Oelkers as its incoming chief executive, with the transition expected by February 1, 2027, potentially providing new leadership as the company shifts toward oncology and other non-COVID products. BioNTech Names Guido Oelkers as Chief Executive
• Neutral Sentiment: BioNTech’s second-quarter adjusted loss of €2.53 per share was narrower than the €2.68 analyst consensus, but revenue of €166.4 million fell short of the €179.4 million estimate. Quarterly revenue declined 59.5% year over year. BioNTech Second Quarter Earnings
• Negative Sentiment: BioNTech cut its 2026 revenue guidance to €1.6–1.9 billion from its previous outlook, citing weaker-than-expected COVID-19 vaccine demand and the timing of milestone-related revenue. Adjusted R&D expenses are expected to remain high at €2.0–2.3 billion. BioNTech Lowers 2026 Sales Outlook
• Negative Sentiment: The earnings report reinforced concerns that declining COVID vaccine sales are outpacing near-term contributions from BioNTech’s pipeline, with first-half sales also reported lower. BioNTech Reports Lower First-Half Sales

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.